Cubist Systematic Strategies’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $9.46M | Buy |
+1,246,696
| New | +$10.4M | 0.05% | 600 |
|
|
2024
Q3 | – | Sell |
-1,112,232
| Closed | -$6.87M | – | 2992 |
|
|
2024
Q2 | $6.87M | Buy |
1,112,232
+935,132
| +528% | +$5.16M | 0.05% | 603 |
|
|
2024
Q1 | $900K | Sell |
177,100
-865,812
| -83% | -$4.87M | 0.01% | 2255 |
|
|
2023
Q4 | $6.25M | Buy |
1,042,912
+392,672
| +60% | +$2.28M | 0.04% | 728 |
|
|
2023
Q3 | $4.6M | Buy |
650,240
+22,533
| +4% | +$162K | 0.03% | 804 |
|
|
2023
Q2 | $4.42M | Buy |
627,707
+175,092
| +39% | +$1.41M | 0.03% | 926 |
|
|
2023
Q1 | $3.77M | Buy |
452,615
+451,300
| +34,319% | +$4.34M | 0.02% | 1152 |
|
|
2022
Q4 | $15.1K | Sell |
1,315
-196,728
| -99% | -$2.45M | ﹤0.01% | 4020 |
|
|
2022
Q3 | $2.5M | Buy |
198,043
+158,821
| +405% | +$2.04M | 0.01% | 1777 |
|
|
2022
Q2 | $415K | Sell |
39,222
-112,852
| -74% | -$1.16M | ﹤0.01% | 3196 |
|
|
2022
Q1 | $2.47M | Buy |
152,074
+143,375
| +1,648% | +$2.3M | 0.02% | 1306 |
|
|
2021
Q4 | $120K | Sell |
8,699
-48,959
| -85% | -$648K | ﹤0.01% | 3157 |
|
|
2021
Q3 | $829K | Sell |
57,658
-11,696
| -17% | -$184K | 0.01% | 1669 |
|
|
2021
Q2 | $1.1M | Buy |
69,354
+27,910
| +67% | +$379K | 0.01% | 1506 |
|
|
2021
Q1 | $421K | Sell |
41,444
-415,120
| -91% | -$4.28M | 0.01% | 2054 |
|
|
2020
Q4 | $3.4M | Buy |
456,564
+444,949
| +3,831% | +$2.29M | 0.05% | 645 |
|
|
2020
Q3 | $40K | Buy |
11,615
+10,915
| +1,559% | +$46.8K | ﹤0.01% | 2381 |
|
|
2020
Q2 | $3K | Sell |
700
-18,900
| -96% | -$75.5K | ﹤0.01% | 2355 |
|
|
2020
Q1 | $39K | Buy |
19,600
+17,000
| +654% | +$46.8K | ﹤0.01% | 2029 |
|
|
2019
Q4 | $9K | Buy |
+2,600
| New | +$6.54K | ﹤0.01% | 2370 |
|
|
2019
Q3 | – | Sell |
-27,016
| Closed | -$102K | – | 2225 |
|
|
2019
Q2 | $102K | Buy |
27,016
+15,924
| +144% | +$95.8K | ﹤0.01% | 2231 |
|
|
2019
Q1 | $90K | Buy |
11,092
+1,155
| +12% | +$9.89K | ﹤0.01% | 2017 |
|
|
2018
Q4 | $80K | Sell |
9,937
-7,957
| -44% | -$61.9K | ﹤0.01% | 1798 |
|
|
2018
Q3 | $137K | Buy |
17,894
+3,694
| +26% | +$24.8K | 0.01% | 1533 |
|
|
2018
Q2 | $81K | Buy |
+14,200
| New | +$78.2K | ﹤0.01% | 1583 |
|
|
2017
Q2 | – | Sell |
-14,016
| Closed | -$118K | – | 1674 |
|
|
2017
Q1 | $118K | Buy |
+14,016
| New | +$97.5K | 0.01% | 1355 |
|
|
2016
Q2 | – | Sell |
-47,804
| Closed | -$135K | – | 1721 |
|
|
2016
Q1 | $135K | Buy |
+47,804
| New | +$212K | 0.01% | 1340 |
|
|
2015
Q3 | – | Sell |
-38,290
| Closed | -$572K | – | 1860 |
|
|
2015
Q2 | $572K | Buy |
+38,290
| New | +$435K | 0.03% | 877 |
|
Other funds holding BCRX
DM
KCM
Cubist Systematic Strategies's BCRX Position: Q3 2025 in Review
Cubist Systematic Strategies opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2025: 1,246,696 shares worth $9.46M. The stake represents 0.05% of the portfolio and ranks #600 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in BCRX as recently as Q2 2024.
Cubist Systematic Strategies first reported a position in BCRX in Q2 2015 and has held it in 28 quarters since. 286 funds tracked by Wall St. Rank hold BCRX as of Q3 2025.
- Cubist Systematic Strategies held 1,246,696 shares of BioCryst Pharmaceuticals worth $9.46M as of Q3 2025.
- BioCryst Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
- BioCryst Pharmaceuticals made up 0.05% of Cubist Systematic Strategies's portfolio in Q3 2025, its #600 holding.
- Cubist Systematic Strategies first reported a position in BioCryst Pharmaceuticals in Q2 2015 and has held it in 28 quarters since.
- 286 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.